These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 4564156)

  • 21. [Animal experimental studies on oral immunization with vaccinia virus. I].
    Hochstein-Mintzel V; Huber H; Stickl H
    Zentralbl Bakteriol Orig; 1969 Dec; 212(1):41-9. PubMed ID: 5386253
    [No Abstract]   [Full Text] [Related]  

  • 22. The immune response to infection with vaccinia virus in mice. I. Infection and the production of antibody neutralizing cell-associated and cell-free virus.
    Hutt LM
    J Hyg (Lond); 1975 Jun; 74(3):301-14. PubMed ID: 168248
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction and in Vitro demonstration of cellular immunity to DNA and RNA viruses in guinea-pigs.
    Koszinowski U; Bandlow G
    Clin Exp Immunol; 1975 Apr; 20(1):143-54. PubMed ID: 173485
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Studies on antigenicity, toxicity & pharmacologic activities of soluble antigen of vaccinia virus.
    Singh LM
    Indian J Exp Biol; 1972 Sep; 10(5):344-6. PubMed ID: 4121207
    [No Abstract]   [Full Text] [Related]  

  • 25. Vaccinia virus strain differences. I. Neutralization of vaccinia virus strains by homologous and heterologous antisera.
    Dunlap RC; Barker LF
    Arch Gesamte Virusforsch; 1973; 42(2):107-16. PubMed ID: 4126981
    [No Abstract]   [Full Text] [Related]  

  • 26. Sensitivity of rat macrophages to the vaccinia virus.
    Jandásek L; Votava M
    Z Immunitatsforsch Allerg Klin Immunol; 1970 Jun; 139(5):439-44. PubMed ID: 4247035
    [No Abstract]   [Full Text] [Related]  

  • 27. A recombinant vaccinia virus containing the papilloma E2 protein promotes tumor regression by stimulating macrophage antibody-dependent cytotoxicity.
    Rosales C; Graham VV; Rosas GA; Merchant H; Rosales R
    Cancer Immunol Immunother; 2000 Sep; 49(7):347-60. PubMed ID: 10999461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of interferon in protection of rabbits against rinderpest virus.
    Fujisaki Y; Ishii S; Watanabe M
    Natl Inst Anim Health Q (Tokyo); 1968; 8(3):122-31. PubMed ID: 5712545
    [No Abstract]   [Full Text] [Related]  

  • 29. The immune response to infection with vaccinia virus in mice. II. Appearance of hypersensitivity, production of macrophage migration inhibitory factor and transformation of spleen cells in response to virus antigens.
    Hutt LM
    J Hyg (Lond); 1975 Jun; 74(3):315-27. PubMed ID: 1056960
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Study of attenuated strain of myxoma virus].
    Maral R
    C R Acad Hebd Seances Acad Sci D; 1970 Aug; 271(8):737-9. PubMed ID: 4992294
    [No Abstract]   [Full Text] [Related]  

  • 31. [Approach to the development of an actovaccine using vaccinia virus as a model].
    Chimishkian KL; Svet-Moldavskiĭ GIa
    Vopr Virusol; 1975; (3):273-8. PubMed ID: 1162946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune response in humans after vaccination with vaccinia virus: generation of a virus-specific cytotoxic activity by human peripheral lymphocytes.
    Perrin LH; Zinkernagel RM; Oldstone MB
    J Exp Med; 1977 Oct; 146(4):949-69. PubMed ID: 302316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro stimulation of sensitized lymphocytes by herpes simplex virus and vaccinia virus.
    Rosenberg GL; Farber PA; Notkins AL
    Proc Natl Acad Sci U S A; 1972 Mar; 69(3):756-60. PubMed ID: 4335071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Infection of rabbit alveolar macrophages with a neurotropic vaccinia virus strain in vitro.
    Benda R; Danes L; Cinátl J
    Acta Virol; 1970 Sep; 14(5):353-61. PubMed ID: 4394660
    [No Abstract]   [Full Text] [Related]  

  • 35. Characterization of surface antigen on cells infected by fibroma virus.
    Tompkins WA; Crouch NA; Tevethia SS; Rawls WE
    J Immunol; 1970 Nov; 105(5):1181-9. PubMed ID: 4321290
    [No Abstract]   [Full Text] [Related]  

  • 36. Increase in preexisting cellular antigen-combining groups at different times after infection with different viruses.
    Tarro G; Sabin AB
    Proc Natl Acad Sci U S A; 1970 Oct; 67(2):731-7. PubMed ID: 4331719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of human leukocyte interferon on vaccinia-and herpes virus-infected cell cultures and monkey corneas.
    Neumann-Haefelin D; Sundmacher R; Sauter B; Karges HE; Manthey KF
    Infect Immun; 1975 Jul; 12(1):148-55. PubMed ID: 166924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neutralization assay using a modified vaccinia virus Ankara vector expressing the green fluorescent protein is a high-throughput method to monitor the humoral immune response against vaccinia virus.
    Cosma A; Bühler S; Nagaraj R; Staib C; Hammarin AL; Wahren B; Goebel FD; Erfle V; Sutter G
    Clin Diagn Lab Immunol; 2004 Mar; 11(2):406-10. PubMed ID: 15013995
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of the virus-serum incubation period upon vaccinia virus serum neutralization titers.
    Katz JB
    J Biol Stand; 1987 Oct; 15(4):389-92. PubMed ID: 3680308
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine--induced immunity.
    He Y; Manischewitz J; Meseda CA; Merchlinsky M; Vassell RA; Sirota L; Berkower I; Golding H; Weiss CD
    J Infect Dis; 2007 Oct; 196(7):1026-32. PubMed ID: 17763325
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.